General
Preferred name
TOFISOPAM
Synonyms
Emandaxin ()
Grandaxin ()
P&D ID
PD009199
CAS
22345-47-7
Tags
drug
available
Approved by
PMDA
Drug indication
Hyperuricaemia
Anxiety
Irritable bowel syndrome
Drug Status
approved
experimental
investigational
Max Phase
2.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PHARMACODYNAMICS
Like other benzodiazepines, tofisopam possesses anxiolytic properties but unlike other benzodiazepines it does not have anticonvulsant, sedative, skeletal muscle relaxant, motor skill-impairing or amnestic properties. It enhances the anticonvulsant activity of 1,4-benzodiazepines like diazepam but not sodium valproate, carbamazepine, phenobarbital, or phenytoin.
DESCRIPTION
Tofisopam, a 2,3-benzodiazepine compound, is an orally active anxiolytic agent. Tofisopam can inhibit phosphodiesterase PDE isoenzyme activity[1][2].
PRICE
71
DESCRIPTION
Tofisopam (Grandaxin) is a 2,3-benzodiazepine compound with anxiolytic activity that can be taken orally.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
9
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
25
Molecular Weight
382.19
Hydrogen Bond Acceptors
6
Hydrogen Bond Donors
0
Rotatable Bonds
6
Ring Count
3
Aromatic Ring Count
2
cLogP
4.44
TPSA
61.64
Fraction CSP3
0.36
Chiral centers
1.0
Largest ring
7.0
QED
0.74
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
Phosphodiesterase (PDE)
Pathway
Metabolic Enzyme/Protease
Source data
